Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Hematologic Neoplasms 1Hematologic Diseases 1

Interventions

Cyclophosphamide 6fludarabine 5Exercise 4Blood Specimen Collection 4Immunotherapy, Adoptive 3thymoglobulin 2pegylated granulocyte colony-stimulating factor 2Voriconazole 2Surveys and Questionnaires 2Stem Cell Transplantation 2Physical Therapy Modalities 2Parenteral Nutrition 2Etoposide 2Cytarabine 2CF regimen 2BNT162 Vaccine 2Azacitidine 2venetoclax 1trihexyltetradecylphosphonium chloride 1treosulfan 1shengxuening 1ruxolitinib 1ramosetron 1monalizumab 1glucarpidase 1fludarabine phosphate 1ferrous succinate 1eltrombopag 1dexamethasone 21-phosphate 1Whole-Body Irradiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Hematologic Neoplasms × AC protocol × Clear all
NCT04243434 2020-04-16

PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients

Acrotech Biopharma Inc.

Phase 1 Unknown
56 enrolled
Other hematologic neoplasm

Hematologic Diseases, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡